Small for Gestational Age
31
4
4
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.5%
2 terminated out of 31 trials
91.7%
+5.2% vs benchmark
35%
11 trials in Phase 3/4
18%
4 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (31)
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)
Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)
A Trial of YPEG-rhGH in Children With Short Stature
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.
Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
Observational Prospective Study on Patients Treated With Norditropin®
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation